← Back to Search

PET/CT Imaging for Kidney Cancer

Phase < 1
Recruiting
Led By Melissa Huynh, MD
Research Sponsored by Western University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Men and women with histologically-proven, metastatic renal cell carcinoma (RCC) (TNM stage Tany, Nany, M1)
Be older than 18 years old
Must not have
Unable to lie flat for 30 minutes for the scan
Histology does not have any clear cell component
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to determine if a type of imaging called positron emission tomography (PET) with a specific marker can help detect hidden metastatic kidney cancer. Depending on the extent of the cancer spread

Who is the study for?
This trial is for individuals with metastatic clear cell renal cell carcinoma. It's designed to see if a new type of PET/CT scan can find hidden cancer spread better than current methods.
What is being tested?
[18F] PSMA-1007 PET/CT imaging is being tested to improve the detection of metastases in kidney cancer, which could influence treatment decisions between surgery, radiation, or systemic therapy.
What are the potential side effects?
The side effects are not detailed here but generally include reactions related to the injection of the tracer used for PET/CT scans and exposure to radiation during the imaging process.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with advanced kidney cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot lie flat for 30 minutes.
Select...
My cancer does not have clear cell features.
Select...
I am under 18 years old.
Select...
I am unable to understand and agree to the study's details on my own.
Select...
My liver isn't working properly.
Select...
I need urgent cancer treatment before a PSMA scan can be done.
Select...
I have had cancer treatment before, but not for skin cancer.
Select...
I have had cancer before, but not skin cancer.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in management
Number of metastatic lesions
Secondary study objectives
Pathologic correlates

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: [18F] PSMA-1007 PET/CTExperimental Treatment1 Intervention
All patients enrolled undergo a \[18F\] PSMA-1007 PET/CT

Find a Location

Who is running the clinical trial?

Western UniversityLead Sponsor
29 Previous Clinical Trials
128,701 Total Patients Enrolled
Melissa Huynh, MDPrincipal InvestigatorWestern University
1 Previous Clinical Trials
30 Total Patients Enrolled
~0 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top